The COVID-19 coronavirus pandemic has dramatically and fundamentally changed the usual approaches to doing business. The global and domestic pharmaceutical industries also had to promptly make adjustments to production plans. According to Dmytro Shymkiv, the chairman of the board of directors of Darnitsa Group, the “Darnitsa” company has used all its resources to provide Ukrainians with essential drugs to the maximum extent possible in the conditions of the epidemic. That is why there was no shortage of medicines produced by “Darnitsa” during the entire period of the coronavirus crisis in Ukraine.
The top manager also noted that the plant produces a range of drugs used in the treatment of patients with Covid-19. First of all, these are, of course, antipyretics, in particular, paracetamol. In 2019, it was produced 200% more than previously planned, since the company’s management clearly understood that Ukrainians would definitely need such a medicine. The “Darnitsa” company has done everything possible to ensure uninterrupted supply of this effective antipyretic agent, included in the Covid-19 treatment protocol and recommended by the WHO, to pharmacy chains. In addition to paracetamol, the plant increased its capacity for the production of infusion solutions used in intensive care, medicines used for significant lung damage, as well as drugs for treating such consequences of the disease as thrombosis. At the same time, the pharmaceutical concern “Darnitsa” managed to preserve and increase the main production of drugs for the prevention of dysfunctions and the therapy of the cardiovascular and nervous systems. According to the statistics provided by Shymkiv, the vast majority of Ukrainians suffer from diseases of the central nervous system, heart and blood vessels, which leads to a significant increase in mortality rates.
Dmytro Shymkiv assured that the management of the pharmaceutical company “Darnitsa” approved a work plan in the conditions of the pandemic back in March last year. Now, the specialists of the concern continue to improve the strategy, adapting it to new challenges. Thanks to an integrated approach, which includes mandatory vaccination against the influenza virus for all employees of the Darnitsa Group concern, their medical insurance and the transfer of most of the office staff to remote work, the company was able to protect its employees as much as possible from the risk of getting Covid-19.
